Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: STRATTERA
Published 2026-02-16 · Last reviewed 2026-02-23 · 4 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Atomoxetine is a non-stimulant medication for ADHD and functions as a selective norepinephrine reuptake inhibitor. It is not a controlled substance and is often considered when stimulant misuse/diversion risk, tics, or insomnia concerns limit stimulants.
Onset is slower than stimulants (often several weeks). Benefit depends on consistent daily dosing, and early follow-up is commonly used to support adherence and manage tolerability (GI upset, fatigue, insomnia).
Atomoxetine has a boxed warning for increased risk of suicidal ideation in children and adolescents; mood/suicide screening is typically included in pediatric use, and families should be informed about warning signs.
In serious mental illness, atomoxetine may be preferred over stimulants when activation risk is high, but it can still worsen anxiety and (rarely) trigger mania; close monitoring is typical if bipolar spectrum illness is present.
The atomoxetine compare view, the evidence feed, and the print page can support counseling and monitoring conversations.
Atomoxetine is a strong option when stimulant diversion risk is high or when a patient prefers a non-controlled medication. The key failure mode is stopping too early: onset is delayed, so expectation-setting, thoughtful titration, and reassessment after an adequate trial are important.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Selective norepinephrine reuptake inhibition increases noradrenergic signaling in cortical circuits relevant to attention and impulse control.
Benefits develop over weeks rather than hours; scheduled follow-up and objective measures (school/work performance, fewer errors, less impulsivity) are useful to evaluate response.
Compared with stimulants, atomoxetine has lower misuse risk but may be limited by nausea, fatigue, insomnia, and sexual side effects.
Sources: DailyMed label; guideline statements; network meta-analysis context.